IPG 0521
Alternative Names: IPG-0521Latest Information Update: 25 Aug 2023
At a glance
- Originator Immunophage Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Jun 2023 Preclinical trials in Solid tumours in China (Parenteral)
- 02 Jun 2023 Nanjing Immunophage Biotech files an IND application with the regulatory body (Nanjing Immunophage Biotech website, August 2023)
- 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) (Immunophage Biotech website, August 2023)